×
About 153 results

ALLMedicine™ Secondary Prevention Of Coronary Artery Disease Center

Research & Reviews  47 results

In patients with CAD, adding colchicine to evidence-based therapies reduces MACE withou...
https://doi.org/10.7326/ACPJ202103160-030
Annals of Internal Medicine; Bates ER

Mar 2nd, 2021 - Xia M, Yang X, Qian C. Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease. Am J Cardiol. 2021;140:33-8. 33137319.

Canakinumab for secondary prevention of coronary artery disease.
https://doi.org/10.2217/fca-2020-0211
Future Cardiology; Ortega-Paz L, Capodanno D et. al.

Feb 4th, 2021 - Cardiovascular disease manifestations (CVD) are the world's leading cause of death, and their impact on morbidity requires effective prevention strategies of recurrent adverse events. For decades, inflammation has been proposed as a key promoter f...

Tea consumption and its effects on primary and secondary prevention of coronary artery ...
https://doi.org/10.1016/j.clnesp.2020.11.006
Clinical Nutrition ESPEN; Dludla PV, Nkambule BB et. al.

Jan 26th, 2021 - There is a general interest in understanding how the consumption of tea impacts cardiovascular function in individuals at risk of developing cardiovascular disease (CVD). The current review focuses on evidence from randomized controlled trials (RC...

Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary ...
https://doi.org/10.1016/j.amjcard.2020.10.043
The American Journal of Cardiology; Xia M, Yang X et. al.

Nov 3rd, 2020 - Colchicine has shown potential therapeutic benefits in cardiovascular conditions owing to its broad anti-inflammatory properties. Here, we performed a meta-analysis to determine the efficacy and safety of colchicine in patients with coronary arter...

Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078981
Cardiology Journal; Jankowski P, Kosior DA et. al.

May 22nd, 2020 - The highest priority in preventive cardiology is given to patients with established coronary artery disease (CAD). The aim of the study was to assess the current implementation of the guidelines for secondary prevention in everyday clinical practi...

see more →

Clinicaltrials.gov  8 results

Efficacy and Safety of Low-dose Ticagrelor
https://clinicaltrials.gov/ct2/show/NCT03381742

Sep 30th, 2019 - Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the plat...

Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
https://clinicaltrials.gov/ct2/show/NCT03381755

Sep 12th, 2018 - Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the plat...

Cardiac Care Solution for Coronary Disease Follow up
https://clinicaltrials.gov/ct2/show/NCT03565978

Jun 21st, 2018 - The aim of the study is to evaluate the impacts of a cardiac post-discharge management solution in the population of cardiovascular (CVD) patients who were discharged from the hospital. The objectives include two parts: Objective 1: Assess the fea...

Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation
https://clinicaltrials.gov/ct2/show/NCT03198741

May 9th, 2018 - Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor has become the cornerstone for secondary prevention of coronary artery disease. Long-term DAPT is recommended after percutaneous coronary intervention (PCI) in p...

Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults
https://clinicaltrials.gov/ct2/show/NCT02109523

Apr 13th, 2016 - Coronary artery bypass grafting (CABG) surgery is often performed in elderly patients, but non-adherence to post-CABG guideline medications is a common and serious clinical concern in this age group. A recent systematic review found that higher me...

see more →

News  6 results

Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
https://www.mdedge.com/ccjm/article/111934/cardiology/dual-antiplatelet-therapy-acute-coronary-syndromes-how-long-continue?channel=194
Meghana Halkar, MD, A. Michael Lincoff, MD

Sep 1st, 2016 - Percutaneous coronary intervention for acute coronary syndromes has evolved, and so, hand in hand, has antiplatelet therapy. With the advent of clopidogrel and newer agents, several studies demonstrated the benefits of dual antiplatelet therapy in.

Quality Guidelines Issued for Ambulatory Cardiac Care
https://www.mdedge.com/content/quality-guidelines-issued-ambulatory-cardiac-care-0
Alicia Ault

Jun 13th, 2011 - A group of professional societies on June 13 has issued the first set of quality improvement measures that focus on primary and secondary prevention of coronary artery disease and hypertension in the ambulatory setting. The 10 measures were charac.

Cognitive Impairment Associated With Atorvastatin and Simvastatin
https://www.medscape.com/viewarticle/465883

Abstract and Introduction Clinical guidelines for cholesterol testing and management have been updated recently. With the evolving recognition of benefits and intensified recommendations for cholesterol management, many more patients will require ...

Statins May Also Have Antiarrhythmic Effects
https://www.mdedge.com/internalmedicine/article/13376/cardiology/statins-may-also-have-antiarrhythmic-effects
Kate Johnson

BOSTON — Statin therapy significantly reduces the risk of sudden cardiac death independent of its effect on cholesterol, according to a metaanalysis of 12 studies. “This is not a surprise because statins have a variety of effects, and it is these.

Non-vitamin K Antagonist Oral Anticoagulants Beyond Atrial Fibrillation
https://www.medscape.com/viewarticle/923725

The introduction of the non-vitamin K antagonist oral anticoagulants (NOACs) has been a game changer in our management of many thromboembolic conditions. The relative efficacy, safety, and convenience (rapid onset/offset of action, fewer drug and ...

see more →